PharmAsia News Notable Notes: India’s Sun, Dishman Price Targets Raised By Citigroup, Dr Reddy’s Maintained As Hold
This article was originally published in PharmAsia News
NEW DELHI - Following fourth quarter earnings, Citigroup Global Markets hiked the price target for India's Sun and Dishman pharmaceutical companies citing strong and robust guidance and maintained a hold rating on Dr Reddy's saying management needed to present more clarity
You may also be interested in...
NEW DELHI - India's Sun Pharmaceutical said it is "on strong ground" to complete a merger with Taro Pharmaceutical at $10.25 a share, despite a rebuff by the Israel-based firm, as it reported higher than forecast earnings for the fourth quarter ended March 31 on strong sales of generic Protonix (pantoprazole) in the U.S
NEW DELHI - India's second biggest generic drug maker said it expects revenue growth of 25 percent in the financial year started April and gross margins of 50 percent led by improved cost control at its German betapharm unit and growing revenues from custom manufacturing and active pharmaceutical ingredient sales after earnings below expectations for the fourth quarter ended March
NEW DELHI - Efforts by five smaller Indian drug companies to attract contract research and manufacturing stand to benefit from multinational firms cost-cutting efforts in sourcing active pharmaceutical ingredients and increased clinical trials in the country